Retifanlimab plus carboplatin and paclitaxel improves progression-free survival in squamous cell carcinoma of the anal canal
New treatment option for advanced anal canal cancer patients
A randomized controlled trial and a single-arm trial evaluated retifanlimab in patients with metastatic or inoperable locally recurrent squa…
A new drug combination shows promise in slowing the progression of advanced anal canal cancer for patients with limited treatment options.
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma
FDA approves new drug Zynyz for two rare and aggressive types of cancer
The FDA has approved Zynyz, a PD-1 blocking antibody, for two indications: first-line treatment of inoperable locally recurrent or metastati…
FDA approves new drug Zynyz to treat two rare and aggressive cancers: advanced anal cancer and Merkel cell carcinoma.